Filing Details
- Accession Number:
- 0001144204-15-063192
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-11-06 06:00:21
- Reporting Period:
- 2014-12-10
- Filing Date:
- 2015-11-06
- Accepted Time:
- 2015-11-06 06:00:21
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1385508 | Lightlake Therapeutics Inc. | LLTP | Metal Mining (1000) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1551246 | Michael Sinclair | 445 Park Avenue, 9Th Floor New York NY 10022 | Executive Chairman | Yes | Yes | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.001 Per Share | Acquisiton | 2012-01-10 | 5,000 | $0.00 | 37,720 | No | 4 | A | Indirect | Proton Therapy USA |
Common Stock, Par Value $0.001 Per Share | Acquisiton | 2013-10-21 | 20,000 | $0.00 | 57,720 | No | 4 | A | Direct | |
Common Stock, Par Value $0.001 Per Share | Acquisiton | 2015-01-15 | 1,700 | $3.50 | 75,585 | No | 4 | S | Direct | |
Common Stock, Par Value $0.001 Per Share | Acquisiton | 2015-01-16 | 1,700 | $3.69 | 77,285 | No | 4 | A | Direct | |
Common Stock, Par Value $0.001 Per Share | Acquisiton | 2015-01-20 | 1,600 | $3.69 | 78,885 | No | 4 | A | Direct | |
Common Stock, Par Value $0.001 Per Share | Acquisiton | 2015-01-21 | 1,500 | $3.94 | 80,385 | No | 4 | A | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Indirect | Proton Therapy USA |
No | 4 | A | Direct | |
No | 4 | S | Direct | |
No | 4 | A | Direct | |
No | 4 | A | Direct | |
No | 4 | A | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.001 Per Share | Options | Acquisiton | 2013-05-01 | 130,000 | $0.00 | 130,000 | $8.00 |
Common Stock, Par Value $0.001 Per Share | Options | Acquisiton | 2013-05-01 | 105,000 | $0.00 | 105,000 | $10.00 |
Common Stock, Par Value $0.001 Per Share | Options | Acquisiton | 2013-08-01 | 50,000 | $0.00 | 50,000 | $15.00 |
Common Stock, Par Value $0.001 Per Share | Options | Acquisiton | 2013-08-01 | 50,000 | $0.00 | 50,000 | $20.00 |
Common Stock, Par Value $0.001 Per Share | Options | Acquisiton | 2013-12-31 | 75,000 | $0.00 | 75,000 | $6.00 |
Common Stock, Par Value $0.001 Per Share | Options | Acquisiton | 2014-06-15 | 150,000 | $0.00 | 150,000 | $5.00 |
Common Stock, Par Value $0.001 Per Share | Options | Acquisiton | 2014-06-15 | 100,000 | $0.00 | 100,000 | $8.00 |
Common Stock, Par Value $0.001 Per Share | Options | Acquisiton | 2015-10-27 | 250,000 | $0.00 | 250,000 | $7.25 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
475,000 | 2013-05-01 | 2023-04-30 | No | 4 | A | Direct |
580,000 | 2013-05-01 | 2023-04-30 | No | 4 | A | Direct |
630,000 | 2013-08-01 | 2023-07-31 | No | 4 | A | Direct |
680,000 | 2013-08-01 | 2023-07-31 | No | 4 | A | Direct |
755,000 | 2013-12-31 | 2023-12-30 | No | 4 | A | Direct |
905,000 | 2014-06-15 | 2024-06-14 | No | 4 | A | Direct |
1,005,000 | 2014-06-15 | 2024-06-14 | No | 4 | A | Direct |
1,255,000 | 2015-10-27 | 2025-10-26 | No | 4 | A | Direct |
Footnotes
- This Form 4 is a late filing reporting the changes in beneficial ownership of the Reporting Person as of November 6, 2015. This Form 4 was required to be filed within two business days of 12/10/2014, the effective date of the Issuer's Form 8-A registration statement which registered the common stock of the Issuer for the first time under Section 12 of the Exchange Act. The Reporting Person voluntarily filed a Form 3 and a Form 4 on May 31, 2012 and voluntarily filed another Form 4 on January 25, 2013. In December 2014, the Issuer effected a one-for-one hundred reverse stock split of its common stock (the "1:100 Reverse Stock Split"). Unless otherwise noted, all share amounts and exercise prices listed in this Form 3 been retroactively adjusted for the 1:100 Reverse Stock Split as if such stock splits occurred prior to the issuance of such shares, warrants, or options.
- Footnote 1 continued - As of the January 25, 2013 Form 4, the Reporting Person owned 50,820 shares of the Issuer's common stock: 23,820 shares; 15,000 owned indirectly through the Reporting Person's wife; 12,000 owned indirectly through joint pension funds. Since January 25, 2013, the Reporting Person's wife transferred her 15,000 shares to the Reporting Person for no consideration and there are 1,935 shares that the Reporting Person no longer owns whose disposition is unclear. Thus, for purposes of this Form 4, the Reporting Person owned 48,885 shares prior to the first transaction reported on this Form 4.
- Unknown.
- As of the January 25, 2013 Form 4, the Reporting Person owned 345,000 derivative securities: 60,000 shares of common stock issuable upon exercise of stock options and 285,000 shares of common stock issuable upon the exercise of warrants.
- 50,000 vested on 5/1/2013, 50,000 vested on 11/1/2013, and 30,000 vested on 12/31/2013. All expire 10 years after their respective vesting dates.
- Cashless Options.
- 25,000 vested on 5/1/2013, 25,000 vested on 8/1/2013; 25,000 vested on 11/1/13, and 30,000 vested on 12/31/13. All expire 10 years after their respective vesting dates.
- These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of the next trial with respect to the opioid overdose reversal treatment; (B) the entrance into a distribution, licensing, royalty, partnership, collaboration, or other significant transaction with respect to the opioid overdose reversal treatment; or (C) the filing of a New Drug Application with the U.S. Food and Drug Administration with respect to the opioid overdose reversal treatment; and (ii) the Expiration Date.
- These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of three trials on or subsequent to October 23, 2015; or (B) (1) the approval by the U.S. Food and Drug Administration of the New Drug Application with respect to the opioid overdose reversal treatment; and (2) the commencement of two trials on or subsequent to October 23, 2015; and (ii) the Expiration Date.